|
| Exchange Received Time 17/03/2017 14:55:23 Exchange Disseminated Time 17/03/2017 14:55:29 Time Taken 00:00:06 | | This is to inform you that one of the indirect subsidiaries of the Company namely, Taro Pharmaceuticals Inc. (Canada) has entered into an agreement to acquire all of the issued and outstanding shares of Thallion Pharmaceuticals Inc., a Canadian pharmaceutical corporation. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Clause A (1) of Part A , Schedule III of the aforesaid regulations, is attached as per 'Annexure A'. |
|
|